Sultana Camelia, Erscoiu Simona Manuela, Grancea Camelia, Ceausu Emanoil, Ruta Simona
Department of Virology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania ; Emergent Disease Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Hepat Mon. 2013 Feb 28;13(2):e8611. doi: 10.5812/hepatmon.8611. Print 2013 Feb.
Due to a recent alarming increase in the number of HIV-HCV co-infected patients in Romania.
A cross sectional study was conducted to assess the baseline predictors of liver disease evolution.
83 HIV-HCV co-infected patients, untreated for HCV infection, were evaluated for viral replication, liver fibrosis (estimated by a noninvasive marker - FIB4), and plasma levels of IP-10 (interferon-gamma inducible protein 10) - a cytokine associated with an unfavorable outcome of HCV infection.
The median value for HCV viral load was high (6.3 log10 IU/mL), 98.8% of the patients were infected with HCV genotype 1. Although 53% of the patients received antiretroviral therapy (cART), only 31.8% of these achieved undetectable HIV levels. HCV viral load was significantly higher in patients with AIDS (6.4 vs. 6.1 log10IU/mL; P = 0.04), and in those naïve for cART (6.5 vs. 5.9 log10 IU/mL; P = 0.04). Severe fibrosis was directly correlated with immunosupression (56% vs. 17.4%, P = 0.03), HCV replication (6.1 vs. 4.9 log10IU/mL P = 0.008), and IP-10 median values (312 vs. 139 pg/ml, P=0.008). A serum IP-10 level higher than 400 pg/mL was significantly associated with FIB-4 median values (4.09 vs. 1.7, P = 0.004), HCV viral load (6.4 vs. 6.1 log10 IU/mL, P = 0.02) and ALT level (206.8 vs. 112.4 IU/L, P = 0.05).
An important part of the HIV-HCV co-infected patients had negative baseline predictors for the evolution of HCV infection; their therapeutical management must be conducted with special attention towards adherence and potential overlapping drug toxicities. High concentrations of plasma IP-10 are reliable markers for the severity of liver disease.
由于罗马尼亚近期艾滋病毒-丙型肝炎病毒合并感染患者数量惊人地增加。
进行一项横断面研究以评估肝病进展的基线预测因素。
对83例未接受丙型肝炎病毒感染治疗的艾滋病毒-丙型肝炎病毒合并感染患者进行病毒复制、肝纤维化(通过非侵入性标志物FIB4评估)以及血浆IP-10(干扰素-γ诱导蛋白10)水平的评估,IP-10是一种与丙型肝炎病毒感染不良预后相关的细胞因子。
丙型肝炎病毒载量的中位数较高(6.3 log10 IU/mL),98.8%的患者感染丙型肝炎病毒1型。虽然53%的患者接受了抗逆转录病毒治疗(cART),但其中只有31.8%的患者实现了无法检测到的艾滋病毒水平。艾滋病患者的丙型肝炎病毒载量显著更高(6.4对6.1 log10IU/mL;P = 0.04),未接受cART治疗的患者也是如此(6.5对5.9 log10 IU/mL;P = 0.04)。严重纤维化与免疫抑制直接相关(56%对17.4%,P = 0.03)、丙型肝炎病毒复制(6.1对4.9 log10IU/mL,P = 0.008)以及IP-10中位数水平(312对139 pg/ml,P = 0.008)。血清IP-10水平高于400 pg/mL与FIB-4中位数水平(4.09对1.7,P = 0.004)、丙型肝炎病毒载量(6.4对6.1 log10 IU/mL,P = 0.02)以及丙氨酸氨基转移酶水平(206.8对112.4 IU/L,P = 0.05)显著相关。
艾滋病毒-丙型肝炎病毒合并感染患者中有相当一部分在丙型肝炎病毒感染进展方面具有阴性基线预测因素;对他们的治疗管理必须特别关注依从性和潜在的药物重叠毒性。血浆IP-10高浓度是肝病严重程度的可靠标志物。